Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: SLC25A39

Gene summary for SLC25A39

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

SLC25A39

Gene ID

51629

Gene namesolute carrier family 25 member 39
Gene AliasCGI-69
Cytomap17q21.31
Gene Typeprotein-coding
GO ID

GO:0006725

UniProtAcc

Q9BZJ4


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
51629SLC25A39LZE5THumanEsophagusESCC5.83e-035.40e-010.0514
51629SLC25A39LZE7THumanEsophagusESCC1.11e-111.08e+000.0667
51629SLC25A39LZE8THumanEsophagusESCC2.27e-033.71e-010.067
51629SLC25A39LZE20THumanEsophagusESCC4.04e-044.84e-010.0662
51629SLC25A39LZE22D1HumanEsophagusHGIN1.78e-021.63e-010.0595
51629SLC25A39LZE22THumanEsophagusESCC4.28e-041.15e+000.068
51629SLC25A39LZE24THumanEsophagusESCC1.18e-361.40e+000.0596
51629SLC25A39LZE21THumanEsophagusESCC3.90e-037.32e-010.0655
51629SLC25A39LZE6THumanEsophagusESCC1.19e-066.18e-010.0845
51629SLC25A39P1T-EHumanEsophagusESCC1.30e-141.10e+000.0875
51629SLC25A39P2T-EHumanEsophagusESCC1.27e-431.13e+000.1177
51629SLC25A39P4T-EHumanEsophagusESCC8.82e-501.59e+000.1323
51629SLC25A39P5T-EHumanEsophagusESCC4.60e-882.56e+000.1327
51629SLC25A39P8T-EHumanEsophagusESCC3.42e-551.22e+000.0889
51629SLC25A39P9T-EHumanEsophagusESCC1.15e-311.04e+000.1131
51629SLC25A39P10T-EHumanEsophagusESCC1.31e-204.46e-010.116
51629SLC25A39P11T-EHumanEsophagusESCC1.38e-301.78e+000.1426
51629SLC25A39P12T-EHumanEsophagusESCC3.94e-541.05e+000.1122
51629SLC25A39P15T-EHumanEsophagusESCC1.33e-631.64e+000.1149
51629SLC25A39P16T-EHumanEsophagusESCC6.87e-461.14e+000.1153
Page: 1 2 3 4 5 6 7 8 9 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00067791EsophagusESCCporphyrin-containing compound biosynthetic process23/855231/187231.20e-035.88e-0323
GO:00330141EsophagusESCCtetrapyrrole biosynthetic process23/855231/187231.20e-035.88e-0323
GO:00461482EsophagusESCCpigment biosynthetic process40/855262/187232.14e-039.54e-0340
GO:00067832EsophagusESCCheme biosynthetic process20/855227/187232.61e-031.11e-0220
GO:00330132EsophagusESCCtetrapyrrole metabolic process37/855259/187236.23e-032.29e-0237
GO:00424401EsophagusESCCpigment metabolic process50/855284/187237.34e-032.64e-0250
GO:00421681EsophagusESCCheme metabolic process27/855242/187231.16e-023.90e-0227
GO:0033013LiverCirrhotictetrapyrrole metabolic process24/463459/187235.06e-032.62e-0224
GO:0006778LiverCirrhoticporphyrin-containing compound metabolic process20/463449/187239.60e-034.35e-0220
GO:0042168LiverHCCheme metabolic process30/795842/187231.40e-041.13e-0330
GO:00330131LiverHCCtetrapyrrole metabolic process39/795859/187232.14e-041.63e-0339
GO:00067781LiverHCCporphyrin-containing compound metabolic process33/795849/187233.86e-042.62e-0333
GO:0042440LiverHCCpigment metabolic process51/795884/187235.74e-043.65e-0351
GO:0006783LiverHCCheme biosynthetic process19/795827/187233.18e-031.47e-0219
GO:0006779LiverHCCporphyrin-containing compound biosynthetic process21/795831/187234.01e-031.76e-0221
GO:0033014LiverHCCtetrapyrrole biosynthetic process21/795831/187234.01e-031.76e-0221
GO:0046148LiverHCCpigment biosynthetic process37/795862/187234.73e-032.02e-0237
GO:00461481Oral cavityOSCCpigment biosynthetic process36/730562/187231.82e-038.57e-0336
GO:00067831Oral cavityOSCCheme biosynthetic process17/730527/187231.01e-023.49e-0217
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
SLC25A39SNVMissense_Mutationnovelc.512N>Gp.Ala171Glyp.A171GQ9BZJ4protein_codingdeleterious(0.02)probably_damaging(0.992)TCGA-A7-A56D-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyarimidexSD
SLC25A39SNVMissense_Mutationc.788N>Tp.Gly263Valp.G263VQ9BZJ4protein_codingdeleterious(0.03)benign(0.41)TCGA-AR-A24H-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapytamoxiphenSD
SLC25A39insertionFrame_Shift_Insnovelc.120_121insCTTTGGGAGGCTGAGGTGGGTGGATCACCTGAp.Ser41LeufsTer21p.S41Lfs*21Q9BZJ4protein_codingTCGA-BH-A0HK-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyarimidexSD
SLC25A39SNVMissense_Mutationrs748101051c.792N>Gp.Ile264Metp.I264MQ9BZJ4protein_codingdeleterious(0.05)benign(0.071)TCGA-IR-A3LA-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
SLC25A39SNVMissense_Mutationrs757102633c.112N>Tp.Arg38Cysp.R38CQ9BZJ4protein_codingdeleterious(0)possibly_damaging(0.693)TCGA-IR-A3LC-01Cervixcervical & endocervical cancerFemale<65I/IIUnspecificCisplatinComplete Response
SLC25A39SNVMissense_Mutationrs746042795c.832G>Ap.Val278Metp.V278MQ9BZJ4protein_codingdeleterious(0)probably_damaging(0.976)TCGA-5M-AAT6-01Colorectumcolon adenocarcinomaFemale<65III/IVUnknownUnknownPD
SLC25A39SNVMissense_Mutationrs745986185c.638N>Ap.Arg213Hisp.R213HQ9BZJ4protein_codingtolerated(0.25)probably_damaging(0.959)TCGA-AA-3492-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
SLC25A39SNVMissense_Mutationc.575A>Gp.Gln192Argp.Q192RQ9BZJ4protein_codingtolerated(1)benign(0.006)TCGA-AA-3663-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
SLC25A39SNVMissense_Mutationrs139586541c.848N>Ap.Arg283Hisp.R283HQ9BZJ4protein_codingdeleterious(0)possibly_damaging(0.634)TCGA-AA-A022-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
SLC25A39SNVMissense_Mutationc.206N>Gp.Gln69Argp.Q69RQ9BZJ4protein_codingtolerated(0.48)benign(0)TCGA-AZ-6598-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1